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alternative to unfractionated heparin. This was initially
unsuccessful as clot was seen in the surgical field before com-
mencement of CPB. In our case, off-pump surgery was not an
option. We therefore used a synergistic dose of danaparoid
(7500 IU). This resulted in the cessation of clotting and
enabled safe CPB. Platelets and cryoprecipitate were given
after CPB, and postoperative bleeding was not troublesome.
A common factor in both these cases was the perioperative
use of aprotinin. 
We suggested in our case that levels of other adhesive
acute-phase proteins (fibronectin, von Willebrand factor) may
have been elevated enough to allow a functional clot matrix
to form despite adequate lowering of fibrinogen levels by
ancrod or, alternatively, that plasmin inhibition by aprotinin
may have protected clottable ancrod-generated fibrinogen
products from further breakdown and clearance.
Our case and that of Ariano and associates suggest that care
should be exercised when using alternatives to unfractionated
heparin in combination with aprotinin. When off-pump
surgery is not feasible, we believe that a combination of dana-
paroid and ancrod may allow safe CPB. Clearly, more
research into how to manage this difficult group of patients is
justified.
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Cardiopulmonary bypass and heparin-induced
thrombocytopenia: Pitfalls of anticoagulation with
danaparoid
To the Editor:
We read with interest the report by Ariano and associates1
describing the failure of danaparoid anticoagulation for car-
diopulmonary bypass (CPB). We2 previously reported the
case of a patient with heparin-induced thrombocytopenia
who required aortic valve replacement and in whom we
attempted to use ancrod, a defibrinogenating agent, as an
